PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
Status:
Recruiting
Trial end date:
2024-07-23
Target enrollment:
Participant gender:
Summary
Study involves surgery for cytoreduction or laparoscopy to determine if you are a candidate
for tumor debulking or a tissue biopsy. Following this surgery you will receive chemotherapy.
This study will administer 7 days of treatment with a targeted therapy called Lynparza.
Lynparza and/or other PARP inhibitors have been FDA approved for the treatment of ovarian and
breast cancer. Tissue biopsy will be done before a 7 day course of Lynparza in order to
correlate molecular changes to response to treatment. Participation in this trial will
require an additional tumor biopsy which will occur either before or after treatment of
Lynparza.